Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTQR74A)

• DTT Name: Proteinase activated receptor 2 (PAR2) DTT Info
• Gene Name: F2RL1

Molecule-Related Drug & Molecule List

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MEDI0618	DM7GNSY	Osteoarthritis pain	MG30.31	Phase 1	[1]

35 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amidine compound 1	DMUPT9A	Inflammation	1A00-CA43.1	Patented	[2]
Amidine compound 2	DM2UWSX	Inflammation	1A00-CA43.1	Patented	[2]
Amidine compound 3	DMV0QJ4	Inflammation	1A00-CA43.1	Patented	[2]
Amidine compound 4	DM9EGVN	Inflammation	1A00-CA43.1	Patented	[2]
Amidine compound 5	DMMN8OY	Inflammation	1A00-CA43.1	Patented	[2]
Amidine compound 6	DMFNK0L	Inflammation	1A00-CA43.1	Patented	[2]
Benzimidazole derivative 10	DML3PE4	N. A.	N. A.	Patented	[2]
Benzimidazole derivative 8	DMQ75BN	N. A.	N. A.	Patented	[2]
Benzimidazole derivative 9	DMHJ98M	N. A.	N. A.	Patented	[2]
Benzothiazine-carboxamide compound 1	DMJ51VZ	Skin inflammation	EF20.Y	Patented	[2]
Benzothiazine-carboxamide compound 2	DMMP2RT	Skin inflammation	EF20.Y	Patented	[2]
Benzothiazine-carboxamide compound 3	DMI31OD	Skin inflammation	EF20.Y	Patented	[2]
Benzothiazine-carboxamide compound 4	DMSR918	Skin inflammation	EF20.Y	Patented	[2]
Benzothiazine-carboxamide compound 5	DMM7N5E	Skin inflammation	EF20.Y	Patented	[2]
Benzothiazine-carboxamide compound 6	DMW94IQ	Skin inflammation	EF20.Y	Patented	[2]
Imidazopyridazine derivative 3	DMXVOP3	Inflammation	1A00-CA43.1	Patented	[2]
Imidazopyridazine derivative 4	DMIAJMO	Inflammation	1A00-CA43.1	Patented	[2]
Imidazopyridazine derivative 5	DM9SXYH	Inflammation	1A00-CA43.1	Patented	[2]
Imidazopyridazine derivative 6	DM5F1LR	Inflammation	1A00-CA43.1	Patented	[2]
Imidazopyridazine derivative 7	DM5X160	Inflammation	1A00-CA43.1	Patented	[2]
Imidazopyridazine derivative 8	DMF7NXJ	Inflammation	1A00-CA43.1	Patented	[2]
Peptide analog 71	DMSEKZG	N. A.	N. A.	Patented	[2]
Peptide analog 72	DMXU71M	N. A.	N. A.	Patented	[2]
Peptidomimetic analog 6	DMSUD5X	N. A.	N. A.	Patented	[2]
Piperazine derivative 5	DMDFUBH	Atopic dermatitis	EA80	Patented	[2]
Piperazine urea derivative 3	DMNAJWQ	Inflammation	1A00-CA43.1	Patented	[2]
Piperazine urea derivative 4	DM3K7IM	Inflammation	1A00-CA43.1	Patented	[2]
Piperidine derivative 2	DMHXMB4	Inflammation	1A00-CA43.1	Patented	[2]
Piperidine derivative 3	DM80XRM	Inflammation	1A00-CA43.1	Patented	[2]
PMID26936077-Compound-13	DMXK6LV	Gastric ulcer	DA60	Patented	[2]
PMID26936077-Compound-34	DMIZL8D	Gastric ulcer	DA60	Patented	[2]
Quinazoline derivative 10	DMZ3ORT	Chronic obstructive pulmonary disease	CA22	Patented	[2]
Quinazoline derivative 11	DMAH435	Chronic obstructive pulmonary disease	CA22	Patented	[2]
Quinazoline derivative 12	DMVKZU2	Chronic obstructive pulmonary disease	CA22	Patented	[2]
Quinazoline derivative 13	DMFU6OD	Arteriosclerosis	BD40	Patented	[2]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASKH95	DM2DPYQ	Discovery agent	N.A.	Investigative	[3]
GB110	DMWFYJ4	Discovery agent	N.A.	Investigative	[4]
GB88	DMLDVFM	Discovery agent	N.A.	Investigative	[5]

References

• [1] Clinical pipeline report, company report or official report of AstraZeneca
• [2] Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
• [3] Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest. 2003 Jan;111(1):35-41.
• [4] Novel agonists and antagonists for human protease activated receptor 2. J Med Chem. 2010 Oct 28;53(20):7428-40.
• [5] Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol. 2012 Mar;165(5):1413-23.